SMMT

SMMT

USD

Summit Therapeutics Inc. Common Stock

$17.490-0.290 (-1.631%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$17.780

Hoch

$18.120

Tief

$17.370

Volumen

2.88M

Unternehmensfundamentaldaten

Marktkapitalisierung

13.0B

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

4.10M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $15.55Aktuell $17.490Hoch $36.91

Ähnliche Nachrichten

BusinessWire

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the

Mehr anzeigen
Summit Therapeutics to Present at Upcoming Investor Conferences
BusinessWire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the

Mehr anzeigen
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Analyst Upgrades

Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target

Guggenheim analyst Brad Canino reiterates Summit Therapeutics with a Buy and maintains $40 price target.

Mehr anzeigen
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
BusinessWire

Summit Therapeutics Raises $500 Million in Private Placement

Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit,"

Mehr anzeigen
Summit Therapeutics Raises $500 Million in Private Placement
Analyst Upgrades

Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout maintains Summit Therapeutics with a Underweight and raises the price target from $13 to $16.

Mehr anzeigen
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics with a Buy and lowers the price target from $50 to $40.

BusinessWire

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Conference Call to be Held at 8:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.